Comparison · Melanocortin analog
Melanotan-1 vs Melanotan-2
These compounds share a catalog class. That grouping makes their declared properties useful to compare, but does not establish experimental or clinical interchangeability.
For in vitro and laboratory research only. Not for human or veterinary use, diagnosis or treatment. These research materials have not been evaluated by COFEPRIS.
What distinguishes these compounds
Melanotan-1 is an alpha-MSH analogue with norleucine and D-phenylalanine substitutions. Melanotan-2 is a cyclic heptapeptide with a lactam bridge. These structural differences remain relevant even though both sit in the melanocortin class.
The Melanotan-1 entry describes MC1R-related cellular signaling, while Melanotan-2 is described as recognizing several melanocortin receptors with a nonselective profile. A pathway highlighted in a summary should not be mistaken for evidence of absolute receptor exclusivity.
What they are
Melanotan-1: Melanotan-1 is a synthetic analog of alpha-melanocyte-stimulating hormone, with norleucine and D-phenylalanine substitutions described in the literature as determinants of its stability. NDP-alpha-MSH has been studied in in vitro melanocortin receptor binding assays and as a reference for comparing structural variants across subtypes. It has been studied in models of melanogenesis in in vitro studies.
Melanotan-2: Melanotan-2 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone, cyclized through a lactam bridge. In preclinical models, it binds to several melanocortin receptors, including MC1R, MC3R and MC4R, with a nonselective profile. It has been investigated in models of melanocortin signaling in rodent studies.
Mechanisms described in the literature
Melanotan-1: MC1R is a Gs protein-coupled receptor present in melanocytes. Its activation modulates the cyclic AMP pathway and tyrosinase expression in cellular models.
Melanotan-2: Cyclization restricts the peptide's conformation and modifies its relative affinity for receptor subtypes. All of these are Gs protein-coupled receptors in cellular models.
Declared chemical identity, field by field
A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.
| Field | Melanotan-1 | Melanotan-2 |
|---|---|---|
| Chemical name | [Nle4, D-Phe7]-alpha-MSH | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Sequence | Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Molecular formula | C78H111N21O19 | C50H69N15O9 |
| Molecular weight | 1646.9 Da | 1024.2 Da |
| CAS number | 75921-69-6 | 121062-08-6 |
| Form | Lyophilized powder | Lyophilized powder |
| Appearance | White to off-white solid | White to off-white solid |
| Solubility | Soluble in sterile water and bacteriostatic water | Soluble in sterile water and bacteriostatic water |
| Storage | −20 °C, protected from light | −20 °C, protected from light |
| Stability after reconstitution | Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol | Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol |
Laboratory handling: Melanotan-1
Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.
Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.
Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.
Laboratory handling: Melanotan-2
Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.
Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.
Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.
Catalog presentations
Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.
Complete research references
The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.
Sources
- Afamelanotide for Erythropoietic Protoporphyria. — N Engl J Med (2015); PMID 26132941; DOI 10.1056/NEJMoa1411481
- Afamelanotide for Erythropoietic Protoporphyria. — N Engl J Med (2015); PMID 26132941; DOI 10.1056/NEJMoa1411481
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. — JAMA Dermatol (2015); PMID 25230094; DOI 10.1001/jamadermatol.2014.1875
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. — JAMA Dermatol (2015); PMID 25230094; DOI 10.1001/jamadermatol.2014.1875
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. — Clin Pharmacokinet (2017); PMID 28063031; DOI 10.1007/s40262-016-0501-5
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. — Clin Pharmacokinet (2017); PMID 28063031; DOI 10.1007/s40262-016-0501-5
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. — Int J Dermatol (2017); PMID 28266027; DOI 10.1111/ijd.13585
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. — Int J Dermatol (2017); PMID 28266027; DOI 10.1111/ijd.13585
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II — Pharm Biotechnol (1998); PMID 9760697; DOI 10.1007/0-306-47384-4_25
- Discovery and development of novel melanogenic drugs. Melanotan-I and -II — Pharm Biotechnol (1998); PMID 9760697; DOI 10.1007/0-306-47384-4_25
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization — Peptides (2006); PMID 16412534; DOI 10.1016/j.peptides.2005.01.029
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization — Peptides (2006); PMID 16412534; DOI 10.1016/j.peptides.2005.01.029
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums — Dermatology (2021); PMID 34464955; DOI 10.1159/000514492
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums — Dermatology (2021); PMID 34464955; DOI 10.1159/000514492
- Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN Case Rep (2020); PMID 31953620; DOI 10.1007/s13730-020-00447-z
- Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN Case Rep (2020); PMID 31953620; DOI 10.1007/s13730-020-00447-z
- Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. — J Med Chem (1989); PMID 2555512; DOI 10.1021/jm00132a010
- Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. — J Med Chem (1989); PMID 2555512; DOI 10.1021/jm00132a010
- A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. — Rapid Commun Mass Spectrom (2007); PMID 17610239; DOI 10.1002/rcm.3106
- A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. — Rapid Commun Mass Spectrom (2007); PMID 17610239; DOI 10.1002/rcm.3106
- PubMed research record — PMID 6777774
- PubMed research record — PMID 2992767
- PubMed research record — PMID 9671118
- EMA: Scenesse composition and pharmaceutical form